Stock Events

Stock Events

Dimerix Limited 

A$0.33
10
-A$0.01-2.35% Today

Statistics

Day High
0.34
Day Low
0.33
52W High
0.79
52W Low
0.29
Volume
258,302
Avg. Volume
989,405
Mkt Cap
199.33M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Sep 999
A$1.17
Apr 999
A$3.52
Sep 998
A$6.56
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

25FebExpected
Q4 2022
Q2 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-0.02
-0.02
-0.01
-0
Expected EPS
N/A
Actual EPS
-0.024930260977048625

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-26.5MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DXB.AU. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for kidney diseases, similar to Dimerix's focus area.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie competes in the biopharmaceutical space with a strong emphasis on research and development, including treatments for chronic kidney disease.
AMGEN
AMGN
Mkt Cap189.22B
Amgen is a biotech firm with a broad portfolio that includes treatments for kidney diseases, making it a direct competitor.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences is involved in the discovery, development, and commercialization of medicines in areas overlapping with Dimerix, including renal diseases.
Pfizer
PFE
Mkt Cap153.13B
Pfizer is a global pharmaceutical company with a diverse portfolio that includes treatments for kidney diseases, competing in the same therapeutic areas as Dimerix.
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Bristol Myers Squibb has a strong presence in the biopharmaceutical field, with research and development in kidney disease treatments.
Merck
MRK
Mkt Cap300.2B
Merck & Co., Inc. is a global healthcare company that develops medicines, including for kidney diseases, making it a competitor.
Novartis
NVS
Mkt Cap297.35B
Novartis is a global healthcare company with a focus on innovative medicines, including for chronic kidney diseases, competing with Dimerix.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca is a biopharmaceutical company with a wide range of medical therapies, including for kidney diseases, making it a competitor.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson is a diverse healthcare company with pharmaceutical products targeting various diseases, including kidney-related conditions, competing with Dimerix.

About

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia.
Show more...
CEO
Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, Ph.D.
Employees
15
Country
Australia
ISIN
AU000000DXB7

Listings

AU
AU
DXB.AU
OTC Link
US
SBMJF

0 Comments

Share your thoughts

FAQ

What is Dimerix Limited stock price today?▼
The current price of DXB.AU is A$0.33 AUD — it has decreased by -2.35% in the past 24 hours. Watch Dimerix Limited stock price performance more closely on the chart.
What is Dimerix Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Dimerix Limited stocks are traded under the ticker DXB.AU.
Is Dimerix Limited stock price growing?▼
DXB.AU stock has risen by +3.75% compared to the previous week, the month change is a -5.14% fall, over the last year Dimerix Limited has showed a -15.95% decrease.
What is Dimerix Limited market cap?▼
Today Dimerix Limited has the market capitalization of 199.33M
When is the next Dimerix Limited earnings date?▼
Dimerix Limited is going to release the next earnings report on September 02, 2026.
What were Dimerix Limited earnings last quarter?▼
DXB.AU earnings for the last quarter are -0.02 AUD per share, whereas the estimation was N/A AUD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A AUD per share.
What is Dimerix Limited revenue for the last year?▼
Dimerix Limited revenue for the last year amounts to 0 AUD.
What is Dimerix Limited net income for the last year?▼
DXB.AU net income for the last year is -26.5M AUD.
Does Dimerix Limited pay dividends?▼
Yes, DXB.AU dividends are paid semi-annual. The last dividend per share was 1.17 AUD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Dimerix Limited have?▼
As of April 13, 2026, the company has 15 employees.
In which sector is Dimerix Limited located?▼
Dimerix Limited operates in the Health & Wellness sector.
When did Dimerix Limited complete a stock split?▼
The last stock split for Dimerix Limited was on October 23, 2017 with a ratio of 1:20.
Where is Dimerix Limited headquartered?▼
Dimerix Limited is headquartered in Fitzroy, Australia.